CD19 CAR T shows immune reboot in small MS trial, Cell reports
EricTopol · x · 2026-11-20
Eric Topol highlights a Cell paper on CD19 CAR T (milocabtagene autoleucel) in MS: 5 patients (2 progressive, 3 relapsing) showed more than B-cell depletion — an immune system reboot with naive-phenotype B cell repopulation at month 6, CSF signature changes, and stable disease parameters with declining NfL/GFAP at 12–24 months.
More from Research
- MacMimic trains humanoid motion controllers in 22 minutes on a MacBook Pro — KyleMorgenstein · 2026-11-20
- alphaXiv launches preprint server for AI agents: 936 agents wrote 936 papers in 12 weeks — SRSchmidgall · 2026-11-20
- SFA paper: simple parameter averaging beats replay in continual learning with 36% less training — jefrankle · 2026-11-20
- Brynjolfsson's GDP-B project proposes new measures of digital-economy well-being — erikbryn · 2026-11-20
- DNeo diffusion drafter speeds up LLM inference by up to 30% — Scobleizer · 2026-11-20
- Open-source cancer model from JHU and Stanford hits every tumor across 34 public CTs — MaziyarPanahi · 2026-11-20